These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 17011551

  • 1. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K, Noguchi-Shinohara M, Yoshita M, Naiki H, Yamada M.
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [Abstract] [Full Text] [Related]

  • 2. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, El-Agnaf OM, Yamada M.
    Brain Res; 2009 Jan 28; 1251():1-6. PubMed ID: 19071095
    [Abstract] [Full Text] [Related]

  • 3. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM.
    J Alzheimers Dis; 2010 Jan 28; 22(1):87-95. PubMed ID: 20847452
    [Abstract] [Full Text] [Related]

  • 4. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.
    Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T, Mizuno Y, Mochizuki H.
    Exp Neurol; 2008 Apr 28; 210(2):409-20. PubMed ID: 18164295
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 6. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M.
    J Alzheimers Dis; 2011 Nov 15; 24(2):383-91. PubMed ID: 21297274
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.
    Spies PE, Melis RJ, Sjögren MJ, Rikkert MG, Verbeek MM.
    J Alzheimers Dis; 2009 Nov 15; 16(2):363-9. PubMed ID: 19221426
    [Abstract] [Full Text] [Related]

  • 13. Alpha-synuclein, Abeta and Alzheimer's disease.
    Wirths O, Bayer TA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb 15; 27(1):103-8. PubMed ID: 12551731
    [Abstract] [Full Text] [Related]

  • 14. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.
    Neurodegener Dis; 2007 Feb 15; 4(5):366-75. PubMed ID: 17622779
    [Abstract] [Full Text] [Related]

  • 15. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M, Londos E, Minthon L, Nielsen HM.
    J Alzheimers Dis; 2012 Feb 15; 29(1):125-32. PubMed ID: 22207004
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.